A Targeted Alpha-Particle Radiopharmaceutical for Bone Metastatic Breast Cancer
Abstract
The proposed studies will develop and evaluate a new therapeutic strategy for treating breast cancer bone metastasis by disrupting the interactions between breast cancer cells and sensory neurons within bone using alpha particle-emitting radiopharmaceuticals that target the CGRP-CRLR axis. The successful completion of this project will establish a new therapeutic target for cancer-induced bone pain and bone metastatic breast cancer; while providing the foundation required to develop new therapies that will decrease suffering and improve survival of breast cancer patients with bone metastases. During this period, we encountered some personnel changes and COVID-19-related issues which have negatively impacted our productivity. However, Drs. Shiozawa and Wadas are planning on conducting training so that Dr. Shiozawa is able to perform radioactive work at Wake Forest School of Medicine. Despite these setbacks, Drs. Shiozawa and Wadas published a review article relevant to this area in the journal Molecules. This article was featured on the front cover of the issue (https://www.mdpi.com/1420-3049/26/8). Additionally, we have prepared the PTCA-CGRP(sub 27-37) peptides and are developing a CRLR over-expressing viral vector to create the CRLC-over-expressing breast cancer cells which will be used to evaluate the (exp 225)Ac-PTCA-CGRP(sub 27-37) peptides in vitro and in vivo during the next year.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2021
- Accession Number
- AD1144330
Entities
People
- Thaddeus J Wadas
- Yusuke Shiozawa
Organizations
- University of Iowa
- Wake Forest University